The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 29

PMID 33371468

Citations 25

Authors

Jung-Hyun Won

Howard Lee

Affiliations

Soon will be listed here.

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.

Citing Articles

COVID-19 Pandemic- Ethical Challenges for Healthcare Workers Practicing in Resource-Limited Settings.

Fadare J, Adeoti A, Dada S, Dele-Ojo B, Raimi T, Isikekpei B Niger Med J. 2024; 63(1):1-9.

PMID: 38798972 PMC: 11117041. DOI: 10.60787/NMJ-63-1-116.

Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.

Shaik R, Ahmad M, Alzahrani M, Alzerwi N, Alnemare A, Reyzah M Vaccines (Basel). 2022; 10(10).

PMID: 36298554 PMC: 9611897. DOI: 10.3390/vaccines10101689.

Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.

Negru P, Miculas D, Behl T, Bungau A, Marin R, Bungau S Biomed Pharmacother. 2022; 153:113432.

PMID: 36076487 PMC: 9289048. DOI: 10.1016/j.biopha.2022.113432.

A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery.

Maghsoudi S, Taghavi Shahraki B, Rameh F, Nazarabi M, Fatahi Y, Akhavan O Chem Biol Drug Des. 2022; 100(5):699-721.

PMID: 36002440 PMC: 9539342. DOI: 10.1111/cbdd.14136.

Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins.

Chen J, Xu W, Li L, Yi L, Jiang Y, Hao P Front Cell Infect Microbiol. 2022; 12:967493.

PMID: 35923799 PMC: 9339902. DOI: 10.3389/fcimb.2022.967493.

References

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

Ella K, Mohan V . Coronavirus Vaccine: Light at the End of the Tunnel. Indian Pediatr. 2020; 57(5):407-410. PMC: 7240229. View

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

Fantini J, Di Scala C, Chahinian H, Yahi N . Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020; 55(5):105960. PMC: 7128678. DOI: 10.1016/j.ijantimicag.2020.105960. View

Schrezenmeier E, Dorner T . Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155-166. DOI: 10.1038/s41584-020-0372-x. View

Funk C, Laferriere C, Ardakani A . A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020; 11:937. PMC: 7317023. DOI: 10.3389/fphar.2020.00937. View

Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

Graham R, Donaldson E, Baric R . A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013; 11(12):836-48. PMC: 5147543. DOI: 10.1038/nrmicro3143. View

10.

Zou L, Dai L, Zhang X, Zhang Z, Zhang Z . Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Arch Pharm Res. 2020; 43(8):765-772. PMC: 7395211. DOI: 10.1007/s12272-020-01258-7. View

11.

Cohen J . Vaccine designers take first shots at COVID-19. Science. 2020; 368(6486):14-16. DOI: 10.1126/science.368.6486.14. View

12.

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

13.

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

14.

Chan K, Lai S, Chu C, Tsui E, Tam C, Wong M . Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6):399-406. View

15.

Chandwani A, Shuter J . Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2009; 4(5):1023-33. PMC: 2621403. DOI: 10.2147/tcrm.s3285. View

16.

Matthias D, Robertson J, Garrison M, Newland S, Nelson C . Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine. 2007; 25(20):3980-6. DOI: 10.1016/j.vaccine.2007.02.052. View

17.

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

18.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

19.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

20.

Gioia M, Ciaccio C, Calligari P, De Simone G, Sbardella D, Tundo G . Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. Biochem Pharmacol. 2020; 182:114225. PMC: 7501082. DOI: 10.1016/j.bcp.2020.114225. View